Interleukin-1 receptor antagonist: a promising cytokine against human squamous cell carcinomas
Y Ding, J Yi, J Wang, Z Sun - Heliyon, 2023 - cell.com
Y Ding, J Yi, J Wang, Z Sun
Heliyon, 2023•cell.comInflammation, especially chronic inflammation, is closely linked to tumor development. As
essential chronic inflammatory cytokines, the interleukin family plays a key role in
inflammatory infections and malignancies. The interleukin-1 (IL-1) receptor antagonist
(IL1RA), as a naturally occurring receptor antagonist, is the first discovered and can compete
with IL-1 in binding to the receptor. Recent studies have revealed the association of the
polymorphisms in IL1RA with an increased risk of squamous cell carcinomas (SCCs) …
essential chronic inflammatory cytokines, the interleukin family plays a key role in
inflammatory infections and malignancies. The interleukin-1 (IL-1) receptor antagonist
(IL1RA), as a naturally occurring receptor antagonist, is the first discovered and can compete
with IL-1 in binding to the receptor. Recent studies have revealed the association of the
polymorphisms in IL1RA with an increased risk of squamous cell carcinomas (SCCs) …
Abstract
Inflammation, especially chronic inflammation, is closely linked to tumor development. As essential chronic inflammatory cytokines, the interleukin family plays a key role in inflammatory infections and malignancies. The interleukin-1 (IL-1) receptor antagonist (IL1RA), as a naturally occurring receptor antagonist, is the first discovered and can compete with IL-1 in binding to the receptor. Recent studies have revealed the association of the polymorphisms in IL1RA with an increased risk of squamous cell carcinomas (SCCs), including squamous cell carcinoma of the head and neck (SCCHN), cervical squamous cell carcinoma, cutaneous squamous cell carcinoma (cSCC), esophageal squamous cell carcinoma (ESCC), and bronchus squamous cell carcinoma. Here, we reviewed the antitumor potential of IL1RA as an IL-1-targeted inhibitor.
cell.com
以上显示的是最相近的搜索结果。 查看全部搜索结果